ReNeuron (RENE)

ReNeuron Group Plc (ReNeuron) is engaged in clinical-stage stem cell business. The Company is engaged in the research, development and commercial exploitation of stem cell technologies for therapeutic and non-therapeutic applications. It used its stem cell technologies to develop cellbased therapies for disease conditions where the cells can be readily administered off-the-shelf to any eligible patient without the need for additional drug treatments. Its lead therapeutic candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. It is also developing stem cell therapies for other conditions, such as peripheral arterial disease and blindness-causing diseases of the retina. It has a range of stem cell lines for non-therapeutic applications. Its ReNcell products are used in academic and commercial research. Its ReNcellCX and ReNcellVM neural cell lines are marketed globally.

Directors: Michael Hunt (CEO) 49, John Sinden (CSO) 61, Patrick Huggins (Secy.) ,

No. of Employees: 19 No. of Shareholders: n/a

Last Annual	March 31st, 2012
Last Interim	September 30th, 2012
Shares in Issue	774,800,000
Free Float	616.6m (79.6%)

Sector	Healthcare
Industry	Biotechnology & Medical Research
Index	FTSE Aim All Share,
Exchange	London Stock Exchange (AIM)
Eligible for	an ISA? a SIPP?